Donald A Marsh

US Patent:

7029878, Apr 18, 2006

Filed:

Mar 14, 2001

Appl. No.:

10/221461

Inventors:

Donald J. Marsh - Hillsborough NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07K 14/705
C07K 19/00
C12N 15/62
G01N 33/567

US Classification:

435 697, 435 721, 530350, 536 234

Abstract:

The present invention features melanin concentrating hormone receptor (MCH-R) chimeric and fusion proteins. MCH-R chimeric proteins comprise an MCH-R polypeptide region made up of at least two or more polypeptide regions characteristic of MCH-R found in different species. MCH-R fusion proteins comprise an MCH-R polypeptide region and a fluorescent protein region.

US Patent:

7259289, Aug 21, 2007

Filed:

Mar 19, 2002

Appl. No.:

10/472629

Inventors:

Su Qian - Edison NJ, US
Donald J. Marsh - Hillsborough NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A01K 67/027
G01N 33/00

US Classification:

800 18, 800 3, 800 8, 800 9, 800 14

Abstract:

The present invention features viable MCH1R deficient mice. MCH1R deficient mice contain an alteration in one or both MCH1R alleles that substantially reduces expression of a functional MCH1R from the altered allele. Preferably, MCH1R deficient mice are MCH1R −/− knockout mice.

US Patent:

7928058, Apr 19, 2011

Filed:

Feb 16, 2007

Appl. No.:

12/223942

Inventors:

Ranabir Sinha Roy - Edison NJ, US
Elisabetta Bianchi - Rome, IT
Antonello Pessi - Rome, IT
Paolo Ingallinella - Pomezia, IT
Donald J. Marsh - Hillsborough NJ, US
George J. Eiermann - Marlboro NJ, US
Yingjun Mu - Fanwood NJ, US
Yun-Ping Zhou - East Brunswick NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A. - Pomezia (Roma)

International Classification:

A61K 38/00

US Classification:

514 11, 514 117, 514 213, 530300

Abstract:

Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.

US Patent:

8268779, Sep 18, 2012

Filed:

Mar 21, 2011

Appl. No.:

13/052270

Inventors:

Ranabir Sinha Roy - Edison NJ, US
Elisabetta Bianchi - Rome, IT
Antonello Pessi - Rome, IT
Paolo Ingallinella - Pomezia, IT
Donald J. Marsh - Hillsborough NJ, US
George J. Eiermann - Marlboro NJ, US
Yingjun Mu - Fanwood NJ, US
Yun-Ping Zhou - East Brunswick NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 38/00
A61P 3/10

US Classification:

514 48, 514 49, 514 68, 514 69, 530300

Abstract:

Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity.

US Patent:

20040122033, Jun 24, 2004

Filed:

Dec 8, 2003

Appl. No.:

10/730704

Inventors:

Ravi Nargund - East Brunswick NJ, US
Leonardus Van Der Ploeg - Scotch Plains NJ, US
Tung Fong - Somerset NJ, US
Douglas MacNeil - Westfield NJ, US
Howard Chen - Westfield NJ, US
Donald Marsh - Hillsborough NJ, US
Jeffrey Warmke - Edison NJ, US

International Classification:

A61K031/485
A61K031/19

US Classification:

514/282000, 514/571000

Abstract:

The present invention relates to compositions comprising an appetite suppressant and/or a metabolic rate enhancer and/or a nutrient absorption inhibitor useful for the treatment of obesity, and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

US Patent:

20070155660, Jul 5, 2007

Filed:

Dec 6, 2004

Appl. No.:

10/581166

Inventors:

Donald Marsh - Hillsborough NJ, US
Todd Thiele - Chapel Hill NC, US

International Classification:

A61K 38/12

US Classification:

514009000

Abstract:

The present invention relates to methods of inhibiting or reducing voluntary alcohol consumption in a subject comprising administering a selective melanocortin 4 receptor agonist to said subject. The present invention further relates to methods of treating or preventing alcoholism, alcohol abuse, and alcohol related disorders in a subject comprising administering a selective melanocortin 4 receptor agonist to said subject. The present invention further provides for pharmaceutical compositions and medicaments useful in carrying out these methods.

US Patent:

20070244048, Oct 18, 2007

Filed:

Mar 16, 2007

Appl. No.:

11/724846

Inventors:

Donald Marsh - Hillsborough NJ, US
Antonella Pessi - Rome, IT
Maria Bednarek - Colonia NJ, US
Elisabetta Bianchi - Rome, IT
Paolo Ingallinella - Pomezia (Rome), IT
Andrea Peier - Berkeley Heights NJ, US

International Classification:

A61K 38/17
C07K 14/47

US Classification:

514012000, 530324000

Abstract:

Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.

US Patent:

20100075907, Mar 25, 2010

Filed:

Nov 20, 2009

Appl. No.:

12/623085

Inventors:

Donald J. Marsh - Hillsborough NJ, US
Antonello Pessi - Rome, IT
Maria A. Bednarek - Colonia NJ, US
Elisabetta Bianchi - Rome, IT
Paolo Ingallinella - Rome, IT
Andrea M. Peier - Berkeley Height NJ, US

International Classification:

A61K 38/16
C07K 14/00
C07K 7/06
C07K 7/08
A61P 9/00
A61K 38/08
A61K 38/10
A61P 3/00
A61P 35/00

US Classification:

514 12, 530324, 530327, 530328, 530329, 530325, 514 14, 514 15, 514 16, 514 13

Abstract:

Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed.